Table 1.
Clinical characteristics of patients included.
| Parameters | Total (N = 76) | Nivolumab (N = 59) | Durvalumab (N = 17) |
|---|---|---|---|
| N (%) | N (%) | N (%) | |
| Age (years) | |||
| Median | 61 | 62 | 60 |
| Range | 35–74 | 36–74 | 35–72 |
| Gender | |||
| Female | 10 (13.2) | 8 (13.6) | 2 (11.8) |
| Male | 66 (86.8) | 51 (86.4) | 15 (88.2) |
| Histology | |||
| Adenocarcinoma | 42 (55.3) | 32 (54.2) | 10 (58.8) |
| Squamous cell | 34 (44.7) | 27 (45.8) | 7 (41.2) |
| TNM staging* | |||
| III | 11 (14.5) | 11 (18.6) | 0 (0) |
| IV | 65 (85.5) | 48 (81.4) | 17 (100) |
| ECOG score | |||
| 0–1 | 69 (90.8) | 52 (88.1) | 17 (100) |
| 2 | 7 (9.2) | 7 (11.9) | 0 (0) |
| Smoking history | |||
| Yes | 60 (78.9) | 48 (81.4) | 12 (70.6) |
| No | 16 (21.1) | 11 (18.6) | 5 (29.4) |
| Line of treatment | |||
| First | 20 (26.3) | 3 (5.1) | 17 (100) |
| Second | 56 (73.7) | 56 (94.9) | 0 (0) |
*
Based on the AJCC 8th edition.